Biovica signs agreement for DiviTum® TKa with world re-known cancer clinic

2023-10-12 08:45

Biovica, active in cancer monitoring, today announces the signing of an agreement providing access to DiviTum TKa to appropriate patients treated at a leading cancer center in Florida.

This center in Florida is part of a large and well renowned organization that serves all 50 states in US and international representation as well. In total, the organization serves more than 1.3 million patients every year. Florida being the third largest state and represents ~6,5 percent of the US population.

This organization already has a research collaboration with Biovica, resulting in several clinical trials that have been performed.

"We are thrilled to execute this hospital agreement with a well-regarded institution. This cancer center is recognized by patients nationwide for its important role in cancer treatment. The adoption of DiviTum TKa by this entity equips medical oncologists with a valuable tool for the management of breast cancer patients," said Warren Cresswell, President of the Americas at Biovica.


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program